Gastroenterology · Pittsburgh, PA
NPI
1295726693
Since 2005
Specialty
Gastroenterology
Code 173000000X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
5200 Centre Ave, Suite 312
Pittsburgh, PA, 15232
Phone (412) 321-7777
Groups this clinician bills Medicare through
Medicare paid, 2024
$77K
794 services
Medicare patients, 2024
414
Average age 72
Drug cost, 2024
$1.1M
3,139 prescriptions
Company payments, 2025
$1,008
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by M S Ayasso was code 99214 (office e&m - established), 151 times for 112 patients. In total M S Ayasso billed 794 services in 47 codes, and Medicare paid $77K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-08-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 151 | 112 | $85.22 | $13K |
| 45380 Lower GI Endoscopy - Other | Facility | 79 | 79 | $100.09 | $7,907 |
| 43239 Upper GI Endoscopy | Facility | 74 | 71 | $72.32 | $5,352 |
| 45385 Colonoscopy - Lesion Removal | Facility | 51 | 51 | $155.27 | $7,919 |
| G0500 Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | Facility | 40 | 37 | $3.83 | $153 |
| 99215 Office E&M - Established | Office | 37 | 28 | $130.78 | $4,839 |
| 99213 Office E&M - Established | Office | 36 | 31 | $61.56 | $2,216 |
| 45378 Lower GI Endoscopy - Other | Facility | 33 | 33 | $129.99 | $4,290 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 32 | 32 | $162.54 | $5,201 |
| 99232 Hospital E&M - Subsequent | Facility | 30 | 22 | $57.79 | $1,734 |
| 43248 Upper GI Endoscopy | Facility | 30 | 30 | $111.60 | $3,348 |
| 91200 Standard X-ray | Office | 24 | 24 | $22.16 | $532 |
| 43235 Upper GI Endoscopy | Facility | 22 | 21 | $67.21 | $1,479 |
| G0105 Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 15 | 15 | $147.06 | $2,206 |
| 74328 Digestive/Gastrointestinal | Facility | 15 | 13 | $17.43 | $261 |
By year: 2022 $93K for 879 services; 2023 $75K for 774 services; 2024 $77K for 794 services.
Medicare prescription drug claims, 2024
In 2024, the drug M S Ayasso prescribed most often to Medicare patients was Peg 3350-Electrolyte (Sodium Chloride/Nahco3/Kcl/Peg), with 899 prescriptions and refills. In total M S Ayasso wrote 3,139 Medicare prescriptions that cost $1.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg | 899 | 899 | 878 | $19K |
| Famotidine Generic | 279 | 698 | 104 | $4,437 |
| Ursodiol Generic | 262 | 527 | 60 | $68K |
| Omeprazole Generic | 257 | 682 | 94 | $4,611 |
| Pantoprazole Sodium Generic | 196 | 489 | 58 | $3,072 |
| Xifaxan Rifaximin | 74 | 80 | 12 | $254K |
| Furosemide Generic | 60 | 150 | 19 | $329 |
| Spironolactone Generic | 57 | 159 | 22 | $1,363 |
| Lansoprazole Generic | 52 | 118 | 17 | $2,301 |
| Sucralfate Generic | 50 | 85 | 17 | $4,547 |
| Rosuvastatin Calcium Generic | 49 | 126 | 12 | $485 |
| Lactulose Generic | 45 | 59 | 14 | $2,174 |
| Metformin Hcl Er Metformin Hcl | 38 | 89 | Under 11 | $458 |
| Linzess Linaclotide | 36 | 52 | Under 11 | $26K |
| Mycophenolate Mofetil Generic | 36 | 65 | Under 11 | $4,002 |
Brand drugs: 494 claims; generic drugs: 2,645 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid M S Ayasso $1,008 ($1,008 in general payments such as food, travel and fees) from 3 companies. The largest payer was Janssen Biotech, Inc. with $494.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.